Assessment in the hematology/oncology clinic includes a thorough history, repeat CBC with differential, serum erythropoietin (EPO) level, peripheral blood JAK2 mutation analysis, and a physical examination.
Pertinent history No prior history of cardiac or pulmonary disease, and no prior thrombosis
Laboratory test results CBC is consistent with trilineage myeloproliferation: WBC 21,000/µL with no blasts, Hct 66%, and platelets 650,000/µL; EPO is undetectable; and JAK2 mutation analysis is positive.
Imaging Echocardiography was performed due to complaints of chest pain at presentation; however, no abnormal findings are noted.
Physical examination findings BP 150/88, otherwise vital signs are within normal limits. The patient is well-appearing, thin, with flushed cheeks. Cardiac and pulmonary examination findings are unremarkable. No palpable hepatosplenomegaly and no peripheral edema were noted.
The patient did not undergo bone marrow biopsy; however, a diagnosis of polycythemia vera (PV) is made based on the following major diagnostic criteria: Hct greater than 49%, subnormal EPO level, and the presence of JAK2 V617Fmutation. Of note, at the time of this diagnosis, bone marrow biopsy showing hypercellular bone marrow with trilineage proliferation was not a major diagnostic criterium, but this was changed with the 2016 WHO classification and diagnostic criteria for PV.
What is the greatest clinical concern given the above laboratory test findings?
Click to the next page for answers